Computational study of some potential inhibitors of COVID-19: A DFT analysis

Abstract

Background: There is an urgent demand of drug or therapy to control the COVID-19. Until July 22, 2021 the worldwide total number of cases reported is more than 192 million and the total number of deaths reported is more than 4.12 million. Several countries have given emergency permission for use of repurposed drugs for the treatment of COVID-19 patients. This report presents a computational analysis on repurposing drugs—tenofovir, bepotastine, epirubicin, epoprostenol, tirazavirin, aprepitant and valrubicin, which can be potential inhibitors of the COVID-19.

Method: Density functional theory (DFT) technique is applied for computation of these repurposed drug. For geometry optimization, functional B3LYP/6-311G (d, p) is selected within DFT framework.

Results: DFT based descriptors—highest occupied molecular orbital (HOMO)-lowest unoccupied molecular orbital (LUMO) gap, molecular hardness, softness, electronegativity, electrophilicity index, nucleophilicity index and dipole moment of these species are computed. IR and Raman activities are also analysed and studied. The result shows that the HOMO-LUMO gap of these species varies from 1.061 eV to 5.327 eV. Compound aprepitant with a HOMO-LUMO gap of 1.419 eV shows the maximum intensity of IR (786.176 km mol^‒1) and Raman spectra (15036.702 a.u.).

Conclusion: Some potential inhibitors of COVID-19 are studied by using DFT technique. This study shows that epirubicin is the most reactive compound whereas tenofovir is found to be the most stable. Further analysis and clinical trials of these compounds will provide more insight.

Graphical abstract

Keywords

COVID-19 / repurposing drug / density functional theory / HOMO-LUMO / epirubicin / aprepitant

References

[1] KumarA.,Kumar D.,KumarR.,SinghP.,ChandraR. KumariK. (2020) DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2. J. Biomol. Struct. Dyn.,

[2] AhmedK.,Aldosouky M.,AliS. M.,AftabZ.. (2020) Acute care surgery fellowship program acclimatization to the COVID-19 pandemic: Experience from Qatar. Br. J. Surg., 107, e666

[3] Al-Mandhari, (2020). Coming together in the region to tackle COVID-19. East. Mediterr. Health J., 26: 992–993

[4] Al-Tawfiq,J. A., Sattar,A., Al-Khadra,H., Al-Qahtani,S., Al-Mulhim,M., Al-Omoush,O. Kheir,H. (2020). Incidence of COVID-19 among returning travelers in quarantine facilities: A longitudinal study and lessons learned. Travel Med. Infect. Dis., 38: 101901

[5] AtalS.,Fatima Z.BalakrishnanS. (2020) Approval of itolizumab for COVID-19: A premature decision or need of the hour? BioDrugs, 34, 705–711

[6] Bakouny,Z., Hawley,J. E., Choueiri,T. K., Peters,S., Rini,B. I., Warner,J. L. Painter,C. (2020). COVID-19 and cancer: Current challenges and perspectives. Cancer Cell, 38: 629–646

[7] Berekaa,M. (2021). Insights into the COVID-19 pandemic: Origin, pathogenesis, diagnosis, and therapeutic interventions. Front. Biosci. (Elite Ed.), 13: 117–139

[8] Dublin,S., Walker,R. L., Floyd,J. S., Shortreed,S. M., Fuller,S., Albertson-Junkans,L., Harrington,L. B., Greenwood-Hickman,M. A., Green,B. B. Psaty,B. (2021). Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: A cohort study. Am. J. Hypertens., 34: 339–347

[9] Sanders,J. M., Monogue,M. L., Jodlowski,T. Z. Cutrell,J. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA, 323: 1824–1836

[10] Zhu,N., Zhang,D., Wang,W., Li,X., Yang,B., Song,J., Zhao,X., Huang,B., Shi,W., Lu,R. . (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 382: 727–733

[11] Hooshmand,S. A., Ghobadi,M. Z., Hooshmand,S. E., Jamalkandi,S. A., Alavi,S. M. (2020). A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. Mol. Divers., 25: 1717–1730

[12] HsiehK.,Wang Y.,ChenL.,ZhaoZ.,SavitzS., JiangX.,Tang J.KimY. (2020) Drug repurposing for COVID-19 using graph neural network with genetic, mechanistic, and epidemiological validation. Res. Sq.,

[13] Ino,H., Nakazawa,E. (2021). Drug repurposing for COVID-19: Ethical considerations and roadmaps. Camb. Q. Healthc. Ethics, 30: 51–58

[14] Koren,G. (2020). Chloroquine for Covid 19: introducing drug repurposing to medical students. Int. J. Med. Educ., 11: 155–157

[15] Mahdian,S., Ebrahim-Habibi,A. (2020). Drug repurposing using computational methods to identify therapeutic options for COVID-19. J. Diabetes Metab. Disord., 19: 691–699

[16] Masoudi-Sobhanzadeh, (2020). Computational-based drug repurposing methods in COVID-19. Bioimpacts, 10: 205–206

[17] Meyer-Almes,F. (2020). Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. Comput. Biol. Chem., 88: 107351

[18] Mucke,H. A. (2020). COVID-19 and the drug repurposing tsunami. Assay Drug Dev. Technol., 18: 211–214

[19] Soufi,G. J. (2021). Potential inhibitors of SARS-CoV-2: Recent advances. J. Drug Target., 29: 349–364

[20] Soufi,G. J., Hekmatnia,A., Nasrollahzadeh,M., Shafiei,N., Sajjadi,M., Iravani,P., Fallah,S., Iravani,S. Varma,R. (2020). SARS-CoV-2 (COVID-19): New discoveries and current challenges. Appl. Sci. (Basel), 10: 3641

[21] Nasrollahzadeh,M., Sajjadi,M., Soufi,G. J., Iravani,S. Varma,R. (2020). Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses. Nanomaterials (Basel), 10: 1072

[22] Tu,Y. F., Chien,C. S., Yarmishyn,A. A., Lin,Y. Y., Luo,Y. H., Lin,Y. T., Lai,W. Y., Yang,D. M., Chou,S. J., Yang,Y. P. . (2020). A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 21: 2657

[23] Ramkumar,G. R., Srinivasan,S., Bhoopathy,T. J. (2012). Vibrational spectroscopic studies of tenofovir using density functional theory method. J. Chem., 2013: 126502

[24] Patil,V. M., Narkhede,R. R., Masand,N., Cheke,R. S. (2020). Molecular insights into resveratrol and its analogs as SARS-CoV-2 (COVID-19) protease inhibitors. Coronaviruses, 2: 10–27

[25] Jarange,A. B., Patil,S. V., Malkhede,D. D., Deodhar,S. M., Nandre,V. S., Athare,S. V., Kodam,K. M. Gejji,S. (2021). p-sulfonatocalixarene versus p-thiasulfonatocalixarene: encapsulation of tenofovir disoproxil fumarate and implications to ESI-MS, HPLC, NMR, DFT and anti-MRSA activities. J. Incl. Phenom. Macrocycl. Chem., 99: 43–59

[26] Elfiky,A. (2020). Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 253: 117592

[27] Toroz,D. Gould,I. (2019). A computational study of anthracyclines interacting with lipid bilayers: Correlation of membrane insertion rates, orientation effects and localisation with cytotoxicity. Sci. Rep., 9: 2155

[28] Sobczak,A., Lesniewska-Kowiel,M. A., Muszalska,I., Firlej,A., Cielecka-Piontek,J., Tomczak,S., Barszcz,B., Oszczapowics,I. (2017). Stability of epidoxorubicin hydrochloride in aqueous solutions: Experimental and theoretical studies. J. Chem., 2017: 8107140

[29] Samide,A., Tutunaru,B., Varut,R. M., Oprea,B. (2021). Interactions of some chemotherapeutic agents as epirubicin, gemcitabine and paclitaxel in multicomponent systems based on orange essential oil. Pharmaceuticals (Basel), 14: 619

[30] Liu,X. Wang,X. (2020). Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genomics, 47: 119–121

[31] Wang,J. (2020). Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model., 60: 3277–3286

[32] Boyle,N. M., Tenderholt,A. L. Langner,K. (2008). cclib: a library for package-independent computational chemistry algorithms. J. Comput. Chem., 29: 839–845

[33] Ghosh,D. C. (2004). Molecular orbital and density functional study of the formation, charge transfer, bonding and the conformational isomerism of the boron trifluoride (BF3) and ammonia (NH3) donor-acceptor complex. Int. J. Mol. Sci., 239: 5

[34] Parr,R. G. Chattaraj,P. (1991). Principle of maximum hardness. J. Am. Chem. Soc., 113: 1854–1855

[35] Chattaraj,P. K. (1999). Chemical hardness as a possible diagnostic of the chaotic dynamics of rydberg atoms in an external field. J. Phys. Chem., 103: 6122–6126

[36] Sanderson,R. (1951). An interpretation of bond lengths and a classification of bonds. Science, 114: 670–672

[37] Sanderson,R. (1952). Carbon‒carbon bond lengths. Science, 116: 41–42

[38] Sanderson,R. (1955). Partial charges on atoms in organic compounds. Science, 121: 207–208

[39] Sanderson,R. (1952). Electronegativities in inorganic chemistry. J. Chem. Educ., 29: 539

[40] Sanderson,R. (1954). Electronegativities in inorganic chemistry. III. J. Chem. Educ., 31: 238

[41] SandersonR.. T. (1960) Chemical Periodicity. New York: Reinhold Publishing Corporation

[42] Vleeschouwer,F. D., Speybroeck,V. V., Waroquier,M., Geerlings,P. Proft,F. (2007). Electrophilicity and nucleophilicity index for radicals. Org. Lett., 9: 2721

[43] Elfiky,A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. J. Biomol. Struct. Dyn., 2020: 1–9

[44] Hasan,M. K., Kamruzzaman,M., Bin Manjur,O. H., Mahmud,A., Hussain,N., Alam Mondal,M. S., Hosen,M. I., Bello,M. (2021). Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. Heliyon, 7: e06435

[45] Salpini,R., Alkhatib,M., Costa,G., Piermatteo,L., Ambrosio,F. A., Di Maio,V. C., Scutari,R., Duca,L., Berno,G., Fabeni,L. . (2021). Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. J. Antimicrob. Chemother., 76: 396–412

[46] Yun,Y., Song,H., Ji,Y., Huo,D., Han,F., Li,F. (2020). Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification. J. Biomed. Res., 34: 458–469

[47] Toor,H. G., Banerjee,D. I., Lipsa Rath,S. Darji,S. (2021). Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Eur. J. Pharmacol., 890: 173720

[48] Cole,D. J. Hine,N. D. (2016). Applications of large-scale density functional theory in biology. J. Phys. Condens. Matter, 28: 393001

[49] SulpiziM.,Folkers G.,RothlisbergerU.,CarloniP.ScapozzaL. (2002). Mol. Inform., 21, 173

[50] Gaussian 16, Revision A.03. (2016) Gaussian, Inc., Wallingford CT

[51] Foster,M. E. Wong,B. (2012). Nonempirically tuned range-separated DFT accurately predicts both fundamental and excitation gaps in DNA and RNA nucleobases. J. Chem. Theory Comput., 8: 2682–2687

[52] Sun,H., Zhang,S., Zhong,C. (2016). Theoretical study of excited states of DNA base dimers and tetramers using optimally tuned range-separated density functional theory. J. Comput. Chem., 37: 684–693

[53] BalasubramanianK.. (2021) Computational and artificial intelligence techniques for drug discovery and administration. Biomed. Sci.,

[54] ParrR. G.Yang W. (1989) Density Functional Theory of Atoms and Molecules. New York: Oxford University Press

RIGHTS & PERMISSIONS

The Authors (2022). Published by Higher Education Press.